Effectiveness of mevinolin on plasma lipoprotein concentrations in type II hyperlipoproteinemia

https://doi.org/10.1016/0002-9149(86)90733-2Get rights and content

Abstract

Patients with low-density lipoprotein (LDL) concentrations in the top 10th percentile of the population (type II hyperlipoproteinemia [HLP]) are at increased risk for premature cardiovascular disease; however, the incidence of myocardial infarction and death can be decreased by LDL cholesterol reduction. Mevinolin, an inhibitor of endogenous cholesterol synthesis, has been shown to reduce LDL cholesterol concentrations in a subset of type II patients with heterozygous familial hypercholesterolemia (FH). Using a double-blind, randomized, crossover, placebo-controlled trial, the safety and efficacy of mevinolin were compared in 24 patients with type II HLP with heterozygous FH (n = 6) or without FH type II HLP (n = 18). Compared with placebo treatment, both apolipoprotein B and LDL cholesterol levels were reduced (p < 0.01) in both FH and non-FH patients by 28 to 34% with mevinolin treatment. In addition, high-density lipoprotein cholesterol levels were significantly increased (p < 0.001) in both patients with FH (16%) and those with non-FH type II HLP (14%). Patients had no serious or clinically significant adverse effects. Thus, mevinolin is a useful drug for treatment of most patients with elevated plasma LDL cholesterol concentrations.

References (27)

  • Lipid Research Clinics Coronary Primary Prevention Trial. Results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering

    JAMA

    (1984)
  • H Mabuchi et al.

    Effects of an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase on serum lipoproteins and ubiquinone-10 levels in patients with familial hypercholesterolemia

    N Engl J Med

    (1981)
  • DR Illingworth et al.

    Hypocholesterolemic effects of mevinolin in patients with heterozygous familial hypercholesterolemia

    J Clin Invest

    (1984)
  • Cited by (78)

    • Statin treatment is associated with insulin sensitivity decrease in type 1 diabetes mellitus: A prospective, observational 56-month follow-up study

      2016, Journal of Clinical Lipidology
      Citation Excerpt :

      Most statins are similar in structure to the enzyme's substrate, HMG-CoA, and act as competitive inhibitors. Inhibition of this enzyme by statins translates into lowering low-density lipoprotein (LDL) cholesterol via enhanced LDL receptor expression.3,4 As high LDL levels are causally associated with increased cardiovascular disease (CVD), statin treatment is effective in the primary and secondary prevention of CVD that is generally safe and well tolerated.5–8

    • Lipid-Lowering Therapy with Statins for the Primary and Secondary Prevention of Cardiovascular Disease

      2011, Cardiology Clinics
      Citation Excerpt :

      Lovastatin, the first commercially developed statin, was approved for clinical use in 1987. Initial studies on both healthy volunteers15 and those with hypercholesterolemia16 showed a 28% to 45% reduction in LDL levels from baseline. Head-to-head trials were conducted in the late 1980s comparing statins with the other classes of lipid-lowering agents.

    View all citing articles on Scopus
    View full text